Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: May, 2017 | Pages:
80 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) - Pipeline Review, H1 2017 Summary According to the recently published report 'Granulocyte Macrophage Colony Stimulating Factor - Pipeline Review, H1 2017'; Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) pipeline Target constitutes close to 13 molecules. Out of which approximately 12 molecules are developed by companies and remaining by the universities/institutes. Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) - Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a glycoprotein secreted by macrophages, T cells, mast cells, NK cells, endothelial cells and fibroblasts. It stimulates the growth and differentiation of hematopoietic precursor cells from various lineages, including granulocytes, macrophages, eosinophils and erythrocytes. The report 'Granulocyte Macrophage Colony Stimulating Factor - Pipeline Review, H1 2017' outlays comprehensive information on the Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities. It also reviews key players involved in Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 6, 3 and 2 respectively. Similarly, the universities portfolio in Phase II stages comprises 1 molecule, respectively. Report covers products from therapy areas Oncology, Immunology, Central Nervous System and Respiratory which include indications Rheumatoid Arthritis, Breast Cancer, Melanoma, Solid Tumor, Hepatocellular Carcinoma, Multiple Sclerosis, Muscle Invasive Bladder Cancer (MIBC), Pancreatic Cancer, Soft Tissue Sarcoma, Bone Cancer, Chronic Obstructive Pulmonary Disease (COPD), Colon Carcinoma, Juvenile Myelomonocytic Leukemia (JMML), Leukemias, Liver Cancer, Lung Adenocarcinoma, Lung Disease, Lymphoma, Merkel Cell Carcinoma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Breast Cancer, Metastatic Colorectal Cancer, Metastatic Liver Cancer, Metastatic Melanoma, Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer), Osteoarthritis Pain, Plaque Psoriasis (Psoriasis Vulgaris), Prostate Cancer, Psoriasis, Recurrent Head And Neck Cancer Squamous Cell Carcinoma, Renal Cell Carcinoma and Squamous Cell Carcinoma. Scope - The report provides a snapshot of the global therapeutic landscape for Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) - The report reviews Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2)targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2)targeted therapeutics and enlists all their major and minor projects - The report assesses Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) targeted therapeutics Reasons to buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2)development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
Table of Contents
List of Tables List of Figures Introduction Global Markets Direct Report Coverage Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) - Overview Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) - Therapeutics Development Products under Development by Stage of Development Products under Development by Therapy Area Products under Development by Indication Products under Development by Companies Products under Development by Universities/Institutes Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) - Therapeutics Assessment Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) - Companies Involved in Therapeutics Development Aduro BioTech Inc Amgen Inc BriaCell Therapeutics Corp Cold Genesys Inc GlaxoSmithKline Plc Humabs BioMed SA KaloBios Pharmaceuticals Inc Morphotek Inc Sillajen Biotherapeutics Takeda Pharmaceutical Company Ltd Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) - Drug Profiles CG-0070 - Drug Profile Product Description Mechanism Of Action R&D Progress CG0070 + Immune Checkpoint Modulator - Drug Profile Product Description Mechanism Of Action R&D Progress gimsilumab - Drug Profile Product Description Mechanism Of Action R&D Progress GSK-3196165 - Drug Profile Product Description Mechanism Of Action R&D Progress lenzilumab - Drug Profile Product Description Mechanism Of Action R&D Progress Monoclonal Antibody to Inhibit GM-CSF for Immunological Disorders - Drug Profile Product Description Mechanism Of Action R&D Progress namilumab - Drug Profile Product Description Mechanism Of Action R&D Progress OrienX-010 - Drug Profile Product Description Mechanism Of Action R&D Progress pexastimogene devacirepvec - Drug Profile Product Description Mechanism Of Action R&D Progress STINGVAX - Drug Profile Product Description Mechanism Of Action R&D Progress SVBR-1GM - Drug Profile Product Description Mechanism Of Action R&D Progress talimogene laherparepvec - Drug Profile Product Description Mechanism Of Action R&D Progress Vaccine to Target CD40L and GM-CSF for Oncology - Drug Profile Product Description Mechanism Of Action R&D Progress Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) - Dormant Products Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) - Discontinued Products Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) - Product Development Milestones Featured News & Press Releases May 15, 2017: Cold Genesys Announces Clinical Results at American Urological Association Annual Meeting 2017 May 08, 2017: Scottish Medicines Consortium Rejects Imlygic For Use Within NHS Scotland May 08, 2017: BriaCell Announces First Patient Dosed in Phase I/IIa Clinical Study of BriaVax in Advanced Breast Cancer Apr 25, 2017: Cold Genesys Announces Acceptance of Late Breaking Abstract at American Urological Association (AUA) Annual Meeting 2017 Apr 24, 2017: SillaJen And Transgene Announce the Enrollment of the First European Patient in Multinational Phase 3 Trial For Pexa-Vec in Advanced Liver Cancer Apr 12, 2017: Transgene and Institut Bergonie Start the Phase 2 Part of the METROmaJX Trial Mar 15, 2017: BriaCell Receives FDA Clearance to Initiate Phase I/IIa Clinical Trial of BriaVax in Patients with Advanced Breast Cancer Mar 07, 2017: BriaCell Files New Patent Application for its Whole-Cell Breast Cancer Vaccine and Companion Diagnostic Platforms Feb 06, 2017: BriaCell Moves Forward to Initiate Phase I/IIa Clinical Study for BriaVax in Advanced Breast Cancer Dec 05, 2016: BriaCell to Present at a Breast Cancer Symposium, and Enters into a Research Agreement with Terasaki Foundation Laboratory Nov 29, 2016: Kalobios To Present At JMML International Symposium Nov 29, 2016: BriaCell Files a Patent Application for its Companion Diagnostic Platform to complement BriaVax Nov 10, 2016: BriaCell Provides Clinical Development Update on BriaVax Oct 26, 2016: BriaCell Announces the Appointment of Biotechnology Veteran William Williams as New CEO and Director Oct 06, 2016: Talimogene laherparepvec in melanoma: Added benefit not proven Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer
List of Tables
Number of Products under Development by Stage of Development, H1 2017 Number of Products under Development by Therapy Areas, H1 2017 Number of Products under Development by Indications, H1 2017 Number of Products under Development by Indications, H1 2017 (Contd..1), H1 2017 Number of Products under Development by Companies, H1 2017 Products under Development by Companies, H1 2017 Products under Development by Companies, H1 2017 (Contd..1), H1 2017 Products under Development by Companies, H1 2017 (Contd..2), H1 2017 Number of Products under Investigation by Universities/Institutes, H1 2017 Products under Investigation by Universities/Institutes, H1 2017 Number of Products by Stage and Mechanism of Actions, H1 2017 Number of Products by Stage and Route of Administration, H1 2017 Number of Products by Stage and Molecule Type, H1 2017 Pipeline by Aduro BioTech Inc, H1 2017 Pipeline by Amgen Inc, H1 2017 Pipeline by BriaCell Therapeutics Corp, H1 2017 Pipeline by Cold Genesys Inc, H1 2017 Pipeline by GlaxoSmithKline Plc, H1 2017 Pipeline by Humabs BioMed SA, H1 2017 Pipeline by KaloBios Pharmaceuticals Inc, H1 2017 Pipeline by Morphotek Inc, H1 2017 Pipeline by Sillajen Biotherapeutics, H1 2017 Pipeline by Takeda Pharmaceutical Company Ltd, H1 2017 Dormant Products, H1 2017 Dormant Products, H1 2017 (Contd..1), H1 2017 Discontinued Products, H1 2017
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
